# Rami Elghandour

> Rami Elghandour is Chairman and CEO of Arcellx (NASDAQ: ACLX), a clinical-stage biotechnology company developing next-generation cell therapies for cancer and autoimmune diseases. An engineer turned venture capitalist turned serial CEO, he has led two successful IPOs, built two multibillion-dollar public companies, and raised over $1.75 billion in capital. At Arcellx, he transformed the company from an early-stage startup into a commercial-ready organization with a peak valuation exceeding $6 billion, advancing the anito-cel BCMA CAR-T therapy toward FDA approval for relapsed/refractory multiple myeloma. A TEDx speaker on unconscious bias and gender equity, Rami is also an executive producer of the Oscar-nominated documentary 'The Voice of Hind Rajab' and the Sundance-premiered 'American Doctor.'

- **Role:** Chairman & Chief Executive Officer at Arcellx
- **Organizations:** Arcellx, Nevro Corporation, Johnson & Johnson Development Corporation, Advanced Neuromodulation Systems, Action Potential Venture Capital, Sounding Board Inc., CareMessage, YPO
- **Nationality:** American
- **Education:** MBA, Healthcare Management, Wharton School, University of Pennsylvania, BS, Electrical and Computer Engineering, Rutgers University School of Engineering
- **Known for:** Led two successful IPOs (Nevro and Arcellx), Built two multibillion-dollar public companies from early-stage startups, Raised over $1.75 billion in capital across career

## Career timeline

- **2001** — Graduated from Rutgers with BS in Electrical and Computer Engineering
- **2001-2005** — Design Engineer at Advanced Neuromodulation Systems, developing firmware for implantable spinal cord stimulators
- **2006-2008** — MBA at Wharton School, University of Pennsylvania, focus on Healthcare Management
- **2008** — Joined Johnson & Johnson Development Corporation (JJDC) as investor, led several investments including Nevro's Series B financing
- **2007** — Received first U.S. patent for implantable device technology
- **2010** — Received second U.S. patent for wireless communication systems for implantable devices
- **2012** — Joined Nevro Corporation as President and CEO, scaled from 30 to ~1,000 employees
- **2014** — Led Nevro's IPO on NYSE, raising hundreds of millions
- **2019** — Nevro approached $400M in revenue; peak valuation over $3 billion (10x+ increase under his leadership); joined Action Potential Venture Capital as Executive in Residence
- **2021** — Appointed Chairman and Chief Executive Officer of Arcellx (January 22, 2021)
- **2022** — Raised over $1.75 billion in total capital across career; Arcellx advanced anito-cel clinical program
- **2023** — Arcellx went public (NASDAQ: ACLX); anito-cel Phase 2 data showed 97% overall response rate
- **2024** — Arcellx peak valuation exceeded $6 billion; 30x+ value increase under Elghandour leadership; partnership with Kite/Gilead advanced
- **2025** — iMMagine-1 study results presented at EHA; CART-ddBCMA heading toward BLA filing and 2026 commercial launch

## Achievements

- Led two successful IPOs (Nevro and Arcellx)
- Built two multibillion-dollar public companies from early-stage startups
- Raised over $1.75 billion in capital across career
- Grew Nevro from 30 employees to nearly 1,000; peak valuation over $3 billion
- Grew Arcellx to peak valuation exceeding $6 billion (30x+ value increase)
- Generated $320 million in Nevro product sales within 3.5 years of launch
- Holds two U.S. patents for implantable medical device technology
- EY Entrepreneur of the Year - Northern California winner and National Finalist
- Ranked #18 among top 50 large company CEOs (USA Today)
- Ranked #7 Best CEO for Women (CNBC)
- Ranked #11 Best CEO for Diversity (USA Today)
- Bill Campbell 'Man Who Gets It' award from Watermark (2018)
- Diversity Woman Magazine Game Changer - Male Ally Award (2021)
- BLOC 100 Champion Award
- TEDx speaker on unconscious bias and gender equity
- Executive producer of Oscar-nominated documentary 'The Voice of Hind Rajab'
- Executive producer of 'American Doctor' (Sundance Film Festival premiere)
- Anito-cel achieved 97% overall response rate and 93.1% MRD-negative response rate in Phase 2 trials

## Latest updates

- **2025-06** — Arcellx CEO presented iMMagine-1 study results at EHA 2025 for BCMA CAR-T anito-cel
- **2024-12** — Discussed CART-ddBCMA data at ASH 2024 conference
- **2024-01** — Arcellx peak valuation exceeded $6 billion under Elghandour's leadership
- **2023-01** — Arcellx completed IPO on NASDAQ under ticker ACLX
- **2021-01** — Appointed Chairman and CEO of Arcellx on January 22, 2021

## Links

- Website: https://ramielghandour.com/
- LinkedIn: https://www.linkedin.com/in/ramielghandour/
- Twitter/X: https://twitter.com/arcellx
- Instagram: https://www.instagram.com/zainydad/

---

Profile page: https://yespress.io/rami-elghandour
Published by YesPress — https://yespress.io
Last updated: 2026-05-15